Resequencing and association study of vesicular glutamate transporter 1 gene (VGLUT1) with schizophrenia

Schizophrenia Research

Volumn 115, Issue 2-3, 2009, Pages 254-260

  Shen, Yu Chih ^a,b   Liao, Ding Lieh ^c,d   Chen, Jen Yeu ^e   Wang, Ying Chieh ^e   Lai, I Ching ^e   Liou, Ying Jay ^e   Chen, Yu Jun ^f   Luu, Sy Ueng ^g   Chen, Chia Hsiang ^b,d  

^a BUDDHIST TZU CHI GENERAL HOSPITAL   (Taiwan)

^b TZU CHI UNIVERSITY   (Taiwan)

^c Bali Psychiatric Center   (Taiwan)

^d NATIONAL HEALTH RESEARCH INSTITUTES   (Taiwan)

^e YULI VETERANS HOSPITAL   (Taiwan)

^f HUALIEN ARMED FORCES GENERAL HOSPITAL   (Taiwan)

^g TAOYUAN GENERAL HOSPITAL   (Taiwan)

Author keywords

Glutamate; Mutation; Schizophrenia; Vesicular glutamate transporter 1 gene; VGLUT1

Indexed keywords

ALANINE; CYSTEINE; GLYCINE; THREONINE; VESICULAR GLUTAMATE TRANSPORTER 1;

3' UNTRANSLATED REGION; 5' UNTRANSLATED REGION; ADULT; ALLELE; AMINO ACID SUBSTITUTION; ARTICLE; CASE CONTROL STUDY; CHINESE; CONTROLLED STUDY; EXON; FEMALE; GENE FREQUENCY; GENE IDENTIFICATION; GENE SEQUENCE; GENETIC ASSOCIATION; GENETIC SUSCEPTIBILITY; GENETIC VARIABILITY; HUMAN; MAJOR CLINICAL STUDY; MALE; MISSENSE MUTATION; NUCLEOTIDE SEQUENCE; PATHOGENESIS; PRIORITY JOURNAL; PROMOTER REGION; SCHIZOPHRENIA; SINGLE NUCLEOTIDE POLYMORPHISM;

ADULT; EXONS; FEMALE; GENE FREQUENCY; GENETIC PREDISPOSITION TO DISEASE; GENOTYPE; HUMANS; LINKAGE DISEQUILIBRIUM; MALE; MIDDLE AGED; POLYMORPHISM, SINGLE NUCLEOTIDE; SCHIZOPHRENIA; TAIWAN; VESICULAR GLUTAMATE TRANSPORT PROTEIN 1;

EID: 71949095815     PISSN: 09209964     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.schres.2009.08.003     Document Type: Article

References (43)

1. Aihara Y., Mashima H., Onda H., Hisano S., Kasuya H., Hori T., et al. Molecular cloning of a novel brain-type Na(+)-dependent inorganic phosphate cotransporter. J. Neurochem. 74 (2000) 2622-2625
2. Almqvist J., Huang Y., Laaksonen A., Wang D.N., and Hovmoller S. Docking and homology modeling explain inhibition of the human vesicular glutamate transporters. Protein Sci. 16 (2007) 1819-1829
3. Byne W., Dracheva S., Chin B., Schmeidler J.M., Davis K.L., and Haroutunian V. Schizophrenia and sex associated differences in the expression of neuronal and oligodendrocyte-specific genes in individual thalamic nuclei. Schizophr. Res. 98 (2008) 118-128
4. Coyle J.T. MicroRNAs suggest a new mechanism for altered brain gene expression in schizophrenia. Proc. Natl. Acad. Sci. U. S. A. 106 (2009) 2975-2976
5. Craddock N., O'Donovan M.C., and Owen M.J. Phenotypic and genetic complexity of psychosis. Invited commentary on ... Schizophrenia: a common disease caused by multiple rare alleles. Br. J. Psychiatry 190 (2007) 200-203
6. Damberg M. Transcription factor AP-2 and monoaminergic functions in the central nervous system. J. Neural. Transm. 112 (2005) 1281-1296
7. De Gois S., Jeanclos E., Morris M., Grewal S., Varoqui H., and Erickson J.D. Identification of endophilins 1 and 3 as selective binding partners for VGLUT1 and their co-localization in neocortical glutamatergic synapses: implications for vesicular glutamate transporter trafficking and excitatory vesicle formation. Cell. Mol. Neurobiol. 26 (2006) 679-693
8. Delisi L.E. Searching for the true genetic vulnerability for schizophrenia. Genome Med. 1 (2009) 14
9. den Dunnen J.T., and Antonarakis S.E. Nomenclature for the description of human sequence variations. Hum. Genet. 109 (2001) 121-124
10. Duan J., Wainwright M.S., Comeron J.M., Saitou N., Sanders A.R., Gelernter J., et al. Synonymous mutations in the human dopamine receptor D2 (DRD2) affect mRNA stability and synthesis of the receptor. Hum. Mol. Genet. 12 (2003) 205-216
11. Eastwood S.L., and Harrison P.J. Decreased expression of vesicular glutamate transporter 1 and complexin II mRNAs in schizophrenia: further evidence for a synaptic pathology affecting glutamate neurons. Schizophr. Res. 73 (2005) 159-172
12. Fanous A.H., Neale M.C., Webb B.T., Straub R.E., O'Neill F.A., Walsh D., et al. Novel linkage to chromosome 20p using latent classes of psychotic illness in 270 Irish high-density families. Biol. Psychiatry 64 (2008) 121-127
13. Francks C., Tozzi F., Farmer A., Vincent J.B., Rujescu D., St Clair D., et al. Population-based linkage analysis of schizophrenia and bipolar case-control cohorts identifies a potential susceptibility locus on 19q13. Mol. Psychiatry (2008) 10.1038/mp.2008.100
14. Fremeau Jr. R.T., Burman J., Qureshi T., Tran C.H., Proctor J., Johnson J., et al. The identification of vesicular glutamate transporter 3 suggests novel modes of signaling by glutamate. Proc. Natl. Acad. Sci. U. S. A. 99 (2002) 14488-14493
15. Fremeau Jr. R.T., Kam K., Qureshi T., Johnson J., Copenhagen D.R., Storm-Mathisen J., et al. Vesicular glutamate transporters 1 and 2 target to functionally distinct synaptic release sites. Science 304 (2004) 1815-1819
16. Hansen T., Olsen L., Lindow M., Jakobsen K.D., Ullum H., Jonsson E., et al. Brain expressed microRNAs implicated in schizophrenia etiology. PLoS ONE 2 (2007) 873
17. Harrison P.J., Law A.J., and Eastwood S.L. Glutamate receptors and transporters in the hippocampus in schizophrenia. Ann. N. Y. Acad. Sci. 1003 (2003) 94-101
18. Herzog E., Bellenchi G.C., Gras C., Bernard V., Ravassard P., Bedet C., et al. The existence of a second vesicular glutamate transporter specifies subpopulations of glutamatergic neurons. J. Neurosci. 21 (2001) 181
19. Hisano S. Vesicular glutamate transporters in the brain. Anat. Sci. Int. 78 (2003) 191-204
20. Honer W.G., and Young C.E. Presynaptic proteins and schizophrenia. Int. Rev. Neurobiol. 59 (2004) 175-199
21. Javitt D.C. Glutamate and schizophrenia: phencyclidine, N-methyl-d-aspartate receptors, and dopamine-glutamate interactions. Int. Rev. Neurobiol. 78 (2007) 69-108
22. Javitt D.C., and Zukin S.R. Recent advances in the phencyclidine model of schizophrenia. Am. J. Psychiatry 148 (1991) 1301-1308
23. Kraulis P.J., Raine A.R., Gadhavi P.L., and Laue E.D. Structure of the DNA-binding domain of zinc GAL4. Nature 356 (1992) 448-450
24. McClellan J.M., Susser E., and King M.C. Schizophrenia: a common disease caused by multiple rare alleles. Br. J. Psychiatry 190 (2007) 194-199
25. Nudmamud-Thanoi S., Piyabhan P., Harte M.K., Cahir M., and Reynolds G.P. Deficits of neuronal glutamatergic markers in the caudate nucleus in schizophrenia. J. Neural Transm., Suppl. (2007) 281-285
26. Oni-Orisan A., Kristiansen L.V., Haroutunian V., Meador-Woodruff J.H., and McCullumsmith R.E. Altered vesicular glutamate transporter expression in the anterior cingulate cortex in schizophrenia. Biol. Psychiatry 63 (2008) 766-775
27. Parmley J.L., and Hurst L.D. How do synonymous mutations affect fitness?. Bioessays 29 (2007) 515-519
28. Perkins D.O., Jeffries C., and Sullivan P. Expanding the 'central dogma': the regulatory role of nonprotein coding genes and implications for the genetic liability to schizophrenia. Mol. Psychiatry 10 (2005) 69-78
29. Purcell S., Cherny S.S., and Sham P.C. Genetic Power Calculator: design of linkage and association genetic mapping studies of complex traits. Bioinformatics 19 (2003) 149-150
30. Ringstad N., Gad H., Low P., Di Paolo G., Brodin L., Shupliakov O., et al. Endophilin/SH3p4 is required for the transition from early to late stages in clathrin-mediated synaptic vesicle endocytosis. Neuron. 24 (1999) 143-154
31. Sauna Z.E., Kimchi-Sarfaty C., Ambudkar S.V., and Gottesman M.M. The sounds of silence: synonymous mutations affect function. Pharmacogenomics 8 (2007) 527-532
32. Segnitz N., Schmitt A., Gebicke-Härter P.J., and Zink M. Differential expression of glutamate transporter genes after chronic oral treatment with aripiprazole in rats. Neurochem. Int 55 (2009) 619-628
33. Shi Y.Y., and He L. SHEsis, a powerful software platform for analyses of linkage disequilibrium, haplotype construction, and genetic association at polymorphism loci. Cell Res. 15 (2005) 97-98
34. Shigeri Y., Seal R.P., and Shimamoto K. Molecular pharmacology of glutamate transporters, EAATs and VGLUTs. Brain Res. Rev. 45 (2004) 250-265
35. Smirnova L., Grafe A., Seiler A., Schumacher S., Nitsch R., and Wulczyn F.G. Regulation of miRNA expression during neural cell specification. Eur. J. NeuroSci. 21 (2005) 1469-1477
36. Stephan K.E., Baldeweg T., and Friston K.J. Synaptic plasticity and dysconnection in schizophrenia. Biol. Psychiatry 59 (2006) 929-939
37. Sureau A., Gattoni R., Dooghe Y., Stévenin J., and Soret J. SC35 autoregulates its expression by promoting splicing events that destabilize its mRNAs. EMBO J. 20 (2001) 1785-1796
38. Tsai C.J., Sauna Z.E., Kimchi-Sarfaty C., Ambudkar S.V., Gottesman M.M., and Nussinov R. Synonymous mutations and ribosome stalling can lead to altered folding pathways and distinct minima. J. Mol. Biol. 383 (2008) 281-291
39. Venken T., Alaerts M., Souery D., Goossens D., Sluijs S., Navon R., et al. Chromosome 10q harbors a susceptibility locus for bipolar disorder in Ashkenazi Jewish families. Mol. Psychiatry 13 (2008) 442-450
40. Verstreken P., Kjaerulff O., Lloyd T.E., Atkinson R., Zhou Y., Meinertzhagen I.A., et al. Endophilin mutations block clathrin-mediated endocytosis but not neurotransmitter release. Cell 109 (2002) 101-112
41. Vinatier J., Herzog E., Plamont M.A., Wojcik S.M., Schmidt A., Brose N., et al. Interaction between the vesicular glutamate transporter type 1 and endophilin A1, a protein essential for endocytosis. J. Neurochem. 97 (2006) 1111-1125
42. Williams H.J., Owen M.J., and O'Donovan M.C. Schizophrenia genetics: new insights from new approaches. Br. Med. Bull 91 (2009) 61-74
43. Wilson N.R., Kang J., Hueske E.V., Leung T., Varoqui H., Murnick J.G., et al. Presynaptic regulation of quantal size by the vesicular glutamate transporter VGLUT1. J. Neurosci. 25 (2005) 6221-6234